Advertisement

Advertisement

trials

Common Myths about mRNA COVID-19 Vaccine

Teaser: 

Zainab Abdurrahman, BSc, MMath, MD, FRCPC (Paediatrics), FRCPC (Clinical Immunology and Allergy)

Assistant Clinical Professor (Adjunct) of Paediatrics, McMaster University, Hamilton, ON.

CLINICAL TOOLS

Abstract: There are many concerns the general population has over the new mRNA vaccines that have been produced and are now being distributed in countries around the world to help curb the spread of COVID-19. This review helps to debunk the myths around some of the more common concerns.
Key Words: COVID-19, vaccines, mRNA, trials, studies.
The mRNA vaccine is safe and effective for the prevention of COVID-19.
The two mRNA vaccines approved for use in Canada are the Pfizer-Biontech and the Moderna vaccine.
The Ministry of Health updated their guidelines indicating that the vaccine is still recommended for those with allergies.
It is important to discuss and dispel the myths that patients may have surrounding the mRNA vaccines.
The vaccine is safe and effective for the prevention of COVID-19.
Despite the safety and efficacy of the vaccine, patients who receive it should be reminded to continue wearing a mask and physically distance and follow public health guidelines.
To have access to full article that these tools were developed for, please subscribe. The cost to subscribe is $80 USD per year and you will gain full access to all the premium content on www.healthplexus.net, an educational portal, that hosts 1000s of clinical reviews, case studies, educational visual aids and more as well as within the mobile app.
Disclaimer: 
Disclaimer at the end of each page

Going from Research to Practice: Three Falls Prevention Trials

Going from Research to Practice: Three Falls Prevention Trials

Teaser: 

Chris Brymer, MSc, MD, FRCPC
University of Western Ontario,
London, Ontario

Falls are the leading cause of injury admissions to acute care hospitals in Ontario, and are a common cause of admission to an inpatient geriatric assessment unit. Although falls prevention has been an active, ongoing area of geriatric research for many years, the publication of the results of 4 randomized controlled trials in 1999, addressing falls prevention in the outpatient setting, suggests we may be 'turning the corner', going from research to actual practice.

Close et al's January 1999 study published in Lancet, randomized 397 patients, 65 years of age and older, who had presented to an emergency department with a fall and who were provided with either usual care (n=213), or a detailed falls assessment (n=184).1 Intervention patients underwent a detailed assessment of their visual acuity, balance, cognition, affect, and medication use by a physician in a day hospital setting, and had their functional status and home environment assessed by an occupational therapist. Although the intervention was essentially a 'one-time' assessment, follow-up care was recommended in 84% of cases. During a one-year follow-up period, self-reported falls, recurrent falls, and hospital admission were 61%, 67%, and 39% lower, respectively, in the intervention group by comparison with the usual-care group. Follow-up data was available after one year for approximately 77% of the patients in each group.